Key result
Aquapheresis improves weight loss and may cut 90-day AHF rehospitalizations vs IV diuretics, without survival benefit.
Why the study?
Although aquapheresis reduces weight and may decrease 90-day rehospitalization in diuretic-resistant CHF, survival benefits remain unproven and clinical use is limited by adverse effects, cost, and a lack of guidelines.
Does aquapheresis improve fluid removal and reduce rehospitalization in patients with acute congestive heart failure compared to diuretics?
Systematic Review
Does aquapheresis improve fluid removal and reduce rehospitalization in patients with acute congestive heart failure compared to diuretics?
Answers are grounded in this paper and cite their sources.
While aquapheresis effectively removes excess fluid and may reduce short-term rehospitalizations in acute heart failure, its routine use is limited by adverse events, cost, and lack of survival benefit.
Heart failure is a clinical syndrome with considerable morbidity and mortality rates. Recent data published by National Health and Nutrition Examination Survey (NHANES) showed that 6 million Americans are diagnosed with CHF. The prevalence of CHF is expected to increase by 46% from 2012 to 2030. The current therapy for acute CHF exacerbation involves the use of oral or intravenous diuretics. Aquapheresis is a form of slow continuous ultrafiltration where blood is removed by applying negative pressure by the machine, which is then passed through the unique filter across which a set fraction of plasma water is filtered each minute before it is pumped back into the patient. It is almost exclusively used in congestive heart failure patients who are found to be resistant to incremental doses of intravenous diuretics. Several trials have shown that aquapheresis or ultrafiltration (UF) produces more significant reductions in weight and may even decrease the rehospitalization rate within 90 days; however, a greater sample size is needed to obtain results of better statistical significance. Since UF does not improve survival in patients with heart failure, limiting factors to its use include cost, the need for a multidisciplinary team, catheter-related adverse events, and renal side effects. Guidelines need to be established for its use in heart failure.
No takes yet. Share an insight, caveat, or question.
Javed et al. (2023) conducted a systematic review in Acute congestive heart failure. Aquapheresis (Ultrafiltration) vs. Intravenous diuretics was evaluated. Aquapheresis produces more significant reductions in weight and may decrease 90-day rehospitalization rates compared to intravenous diuretics in acute heart failure, but does not improve survival.
Synapse has enriched 10 related papers. Consider them for comparative context: